Novartis
NVS
NVS
1,301 hedge funds and large institutions have $14.7B invested in Novartis in 2024 Q2 according to their latest regulatory filings, with 132 funds opening new positions, 424 increasing their positions, 486 reducing their positions, and 63 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0.12% less ownership
Funds ownership: 6.4% → 6.28% (-0.12%)
11% less call options, than puts
Call options by funds: $219M | Put options by funds: $246M
13% less repeat investments, than reductions
Existing positions increased: 424 | Existing positions reduced: 486
Holders
1,301
Holding in Top 10
15
Calls
$219M
Puts
$246M
Top Buyers
| 1 | +$148M | |
| 2 | +$133M | |
| 3 | +$64.6M | |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$54.7M |
| 5 |
CCMG
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
+$52.3M |
Top Sellers
| 1 | -$88.4M | |
| 2 | -$70.8M | |
| 3 | -$63.9M | |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$59M |
| 5 |
Aristotle Capital Management
Los Angeles,
California
|
-$47.3M |